Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

Outcomes of patients who enroll in active surveillance (AS) programs for prostate cancer (PCa) while taking five-alpha reductase inhibitors (5-ARIs) have not been well defined. We sought to determine the association of 5-ARI use with risk of reclassification in the Canary Prostate Active Surveillance Study (PASS).

Source: The Journal of Urology - August 1, 2018 Category: Urology & Nephrology Authors: James T. Kearns, Anna V. Faino, Jeanette M. Schenk, Lisa F. Newcomb, James D. Brooks, Peter R. Carroll, Atreya Dash, William J. Ellis, Michael Fabrizio, Martin E. Gleave, Todd M. Morgan, Peter S. Nelson, Ian M. Thompson, Andrew Wagner, Yingye Zheng, Danie Source Type: research